Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 4:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 5,453 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: SOLID TUMORS Clear all
Completed Phase 1 Interventional

GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

NCT04601402
View directory record Official record
Conditions
Solid Tumor, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma
Interventions
GEN-001, Avelumab
Drug
Lead sponsor
Genome & Company
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
New Haven, Connecticut • Atlanta, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 16, 2026, 4:02 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

NCT06130553
View directory record Official record
Conditions
Advanced Solid Tumors That Are MTAP Deficient
Interventions
AZD3470, Datopotamab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
San Francisco, California • West Hollywood, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 16, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

MEK162 for Patients With RAS/RAF/MEK Activated Tumors

NCT01885195
View directory record Official record
Conditions
Solid Tumor and Hematologic Malignancies
Interventions
MEK162
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
68
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 16, 2026, 4:02 PM EDT
Active, not recruiting Phase 1 Interventional

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

NCT05277051
View directory record Official record
Conditions
Neoplasms
Interventions
Remzistotug, Dostarlimab, Belrestotug, Nelistotug, GSK5764227
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
San Francisco, California • Charlotte, North Carolina • Oklahoma City, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 16, 2026, 4:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain

NCT03523351
View directory record Official record
Conditions
Metastatic Solid Tumors of Metastatic Disease
Interventions
Radiation Therapy, Systemic Therapy
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
9
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 16, 2026, 4:02 PM EDT
Recruiting Phase 1 Interventional

TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma

NCT07189195
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Malignant Solid Neoplasm, Unresectable Pancreatic Adenocarcinoma
Interventions
TR-002
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 16, 2026, 4:02 PM EDT
Recruiting Phase 1 Interventional

PAS-004 in Patients With Advanced Solid Tumors

NCT06299839
View directory record Official record
Conditions
RAS Mutation, NF1 Mutation, RAF Mutation, Advanced Solid Tumors
Interventions
PAS-004 Capsules, PAS-004 Tablets
Drug
Lead sponsor
Pasithea Therapeutics Corp.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Austin, Texas • Irving, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 16, 2026, 4:02 PM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma

NCT01226277
View directory record Official record
Conditions
Solid Cancers
Interventions
GDC-0917
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 16, 2026, 4:02 PM EDT
Completed Phase 1 Interventional Results available

A Study of IMC-TR1 in Participants With Advanced Solid Tumors

NCT01646203
View directory record Official record
Conditions
Neoplasms, Tumor
Interventions
IMC-TR1
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Nashville, Tennessee • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2019 · Synced Oct 16, 2026, 4:02 PM EDT
Completed Phase 1 Interventional

SU5416 in Treating Patients With Advanced Solid Tumors

NCT00005642
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
semaxanib
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 16, 2026, 4:02 PM EDT
Recruiting Phase 1 Interventional

GTB-5550 in Advanced Solid Tumors

NCT07541573
View directory record Official record
Conditions
Tri-specific Killer Engager, Solid Tumor, Advanced Solid Tumor
Interventions
GTB-5550
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 16, 2026, 4:02 PM EDT
Terminated Phase 1 Interventional Results available

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

NCT03991741
View directory record Official record
Conditions
Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma, Metastatic Head and Neck Cancer, Locally Advanced Refractory/Recurrent Head and Neck Cancer
Interventions
Autologous Tumor Infiltrating Lymphocytes, High-Dose Interleukin 2
Biological
Lead sponsor
Gregory Daniels
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 16, 2026, 4:02 PM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis

NCT00956254
View directory record Official record
Conditions
Mucositis, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Fentanyl sublingual spray
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 16, 2026, 4:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

NCT03459222
View directory record Official record
Conditions
Advanced Cancer
Interventions
Relatlimab, Nivolumab, BMS-986205, Ipilimumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
5
States / cities
Duarte, California • Aurora, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 16, 2026, 4:02 PM EDT
Completed Phase 1 Interventional

SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies

NCT03831295
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Extracranial Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Anti-OX40 Antibody BMS 986178, TLR9 Agonist SD-101
Biological · Drug
Lead sponsor
Ronald Levy
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 16, 2026, 4:02 PM EDT
Completed Phase 1 Interventional

S-3304 in Treating Patients With Advanced Solid Tumors

NCT00033566
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
S-3304
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 16, 2026, 4:02 PM EDT
Completed Phase 1 Interventional

ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00016172
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pegylated liposomal doxorubicin hydrochloride, picoplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Oct 16, 2026, 4:02 PM EDT
Completed Phase 2 Interventional Results available

A Study in Advanced Solid Tumors

NCT01063075
View directory record Official record
Conditions
Solid Tumor
Interventions
Cetuximab, Carboplatin, 5 - FU
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
6
States / cities
Fayetteville, Arkansas • Fairway, Kansas • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 16, 2026, 4:02 PM EDT
Recruiting Phase 2 Interventional

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

NCT07098988
View directory record Official record
Conditions
Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Interventions
Visugromab, Matching placebo for visugromab, Pembrolizumab 200 mg Q3W, Pemetrexed 500 mg/m^2, Carboplatin AUC 5
Biological · Drug
Lead sponsor
CatalYm GmbH
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 16, 2026, 4:02 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Buspirone in Reducing Shortness of Breath in Patients With Cancer

NCT00053846
View directory record Official record
Conditions
Dyspnea, Pulmonary Complications, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
buspirone hydrochloride, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 120 Years
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
15
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Oct 16, 2026, 4:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Fetal, Infant, and Early Childhood Exposures on Adult Cancer Risk in Women

NCT00559039
View directory record Official record
Conditions
Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
questionnaire administration, evaluation of cancer risk factors
Other · Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 89 Years · Female only
Enrollment
128,700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 16, 2026, 4:02 PM EDT
Recruiting Phase 1Phase 2 Interventional

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139
View directory record Official record
Conditions
Breast Cancer, Solid Tumors, Adult
Interventions
STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 16, 2026, 4:02 PM EDT
Terminated Phase 1 Interventional

Hydroxychloroquine in Treating Patients With Solid Tumors Undergoing Radiation Therapy for Bone Metastases

NCT01417403
View directory record Official record
Conditions
Bone Metastases, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
hydroxychloroquine, radiation therapy
Drug · Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2015 · Synced Oct 16, 2026, 4:02 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

NCT03834961
View directory record Official record
Conditions
Central Nervous System Neoplasm, Infantile Fibrosarcoma, Recurrent Acute Leukemia, Refractory Acute Leukemia, Solid Neoplasm
Interventions
Larotrectinib Sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
78
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 16, 2026, 4:02 PM EDT